Unlock instant, AI-driven research and patent intelligence for your innovation.
Use of Ruxolitinib in preparation of drug for treating M2 type acute myeloid leukemia
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for acute myeloid leukemia, applied in the field of application of Ruxolitinib in the preparation of drugs for the treatment of M2 type acute myeloid leukemia
Active Publication Date: 2015-03-11
THE FIFTH PEOPLES HOSPITAL OF SHANGHAI FUDAN UNIV
View PDF4 Cites 2 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, there is no report about Ruxolitinib as a drug for the treatment of leukemia, especially for the treatment of M2 acute myeloid leukemia.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0048] Example 1 In vitro effect of Ruxolitinib and / or rsTRAIL on Kasumi-1 cells
[0052] Kasumi-1 cells: Donated by Professor Zhu Jiang from the Institute of Blood Research, Shanghai Ruijin Hospital, culture medium containing 10% FBS + RPMI1640 at 37°C, 5% CO 2 , cultured in an incubator under saturated humidity, and the cells in the logarithmic phase were taken for experiments.
[0061] Cell culture conditions: Kasumi-1 cells were inoculated in RPMI1640 medium containing 10% FBS under aseptic conditions at 37°C, 5% CO 2 cultured in an incubator.
[0062] Cell passage: After the cells are centrifuged at low speed, the supernatant is discarded, the cells are resuspended in 3-5ml medium, and the cells are transferred to a...
Embodiment 2
[0114] Example 2 Ruxolitinib enhances the mechanism of rsTRAIL inducing apoptosis in Kasumi-1 cells in vitro
[0115] 1. Materials and methods
[0116] 1.1 Materials
[0117] 1.1.1 Primers
[0118] According to the human TRAIL, DR4, DR5, DcR1, DcR2, JAK1, JAK2, mRNA sequences provided by the NCBI database, with β-actin as an internal reference, the primers were designed with the software Primer5.0 and synthesized by Shanghai Sangon Biotechnology Co., Ltd.:
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Property
Measurement
Unit
Concentration
aaaaa
aaaaa
Login to View More
Abstract
The invention relates to use of Ruxolitinib in preparation of a drug for treating M2 type acute myeloid leukemia with t (8; 21) chromosome translocation, and the in-vitro effective concentration is 1 * 10<-6>-1 *10<-5>M. DrugRuxolitinib is not only itself has the effect of inhibiting growth and inducing apoptosis on leukemiacell Kasumi-1, and enhances the drug sensitivity of the leukemiacell Kasumi-1 on rsTRAI by up-regulation of mRNA and protein expression level of DR4, up-regulation of cellapoptosisprotein Bax expression, activation of apoptosisproteincaspase-3 and inhibition of NF-kappa B protein activity. The drug can be used for treating the M2 type acute myeloid leukemia with t (8; 21) chromosome translocation, the new drug for treating the M2 type acute myeloid leukemia with t (8; 21) chromosome translocation is provided, and a new approach for overcoming TRAIL resistance in leukemia cells can be provided.
Description
technical field [0001] The present invention relates to the application of Ruxolitinib in the preparation of medicaments for treating M2 type acute myeloid leukemia, in particular to the application of Ruxolitinib in the preparation of medicaments for the preparation of M2 type acute myeloid leukemia with t(8;21) chromosome translocation. Background technique [0002] Leukemia is a kind of malignant clonal disease of hematopoietic stem and progenitor cells. Due to the enhanced self-renewal of leukemia cells, uncontrolled proliferation, impaired differentiation and blocked apoptosis, leukemia cells stop leaking at different stages of cell development. In the bone marrow and other hematopoietic tissues, a large number of leukemia cells proliferate and accumulate, inhibiting normal hematopoiesis and infiltrating other organs and tissues. The clinical manifestations are hepatosplenomegaly, lymphadenopathy or local mass with varying degrees of anemia, bleeding, infection and bone ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More
IPC IPC(8): A61K31/519A61K38/17A61P35/02
CPCA61K31/519A61K38/191A61K2300/00
Inventor 刘立根庄晏
Owner THE FIFTH PEOPLES HOSPITAL OF SHANGHAI FUDAN UNIV
Login to View More 
